Autoantibodies against tumor‐associated antigens (TAAs) are attractive targets for the development of noninvasive serological tests, which have shown to be useful for predicting high risk of recurrence and/or treatment response.13, 14, 15, 16, 17 In the present study, we conducted a peptide microarray to examine whether humoral immunity participated in the immune process to elicit autoantibodies against MGMT in gliomas, as well as to investigate whether MGMT autoantibodies could be used as biomarkers for monitoring the recurrence and prediction of treatment response of glioma. This evidence concerns the gene MGMT and glioma.